<img src="https://ml.globenewswire.com/Resource/Download/aedaf06c-26f8-482c-ac72-39774eab2c35?size=2" nborder="0" align="left" hspace="5" vspace="5" title="VXRT Logo.jpg" alt="Vaxart, Inc."/>European Patent Office granted Vaxart a new patent, extending intellectual property protection for Vaxart’s Norovirus vaccine program through at least 2036 across key European marketsKEY HIGHLIGHTS: • European Patent Office (EPO) granted Vaxart a new patent: European Patent No. 3791859. The patent formally published today. This patent further protects core IP for Vaxart's oral recombinant norovirus vaccine candidate. • Extended Intellectual Property Protection secured through at least 2036 across 13 major European jurisdictions, including Germany, France, Italy, Spain, and the United Kingdom. • Proprietary Delivery Platform Validation: Protects key aspects of Vaxart's room-temperature stable, needle-free pill technology for the use of against norovirus.SOUTH SAN FRANCISCO, Calif., Aug. 26, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that the European Patent Office (EPO) formally published the grant of European Patent No. 3791859 effective today on August 26, 2026 (European Patent Bulletin 26/35)."Securing this patent expands our global intellectual property portfolio and secures additional protection of our norovirus asset for Europe through at least 2036," said Steven Lo, Chief Executive Officer at Vaxart. "As leaders in oral vaccine development, covering critical aspects of our proprietary delivery approach further solidifies our intellectual property estate. As the industry sees ongoing challenges with traditional injected norovirus candidates, this patent secures our potential advantage in delivering a targeted, oral tablet solution for norovirus, an area of high unmet need."Following grant publication, the patent will be validated in key European territories, including Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Netherlands, Norway, Spain, Sweden, Switzerland, and the United Kingdom.About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart’s strategy, prospects, plans and objectives, results from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as “should,” “believe,” “could,” “potential,” “will,” “expected,” “anticipate,” “plan,” "target," "seek," "intend," "may," "predict," "project," "would," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart’s ability to raise capital pursuant to the purchase agreement with LPC; Vaxart’s ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart’s expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; Vaxart’s expectations with respect to the effectiveness of its product candidates; expectations regarding collaborations, including the Dynavax collaboration; and Vaxart’s cash runway and anticipated funding needs. These forward-looking statements are based on current expectations, estimates, forecasts, and projections about the industry and markets in which Vaxart operates as well as management’s current beliefs and assumptions. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart’s product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart’s product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart’s or its partners’ control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart’s capital resources may be inadequate; Vaxart’s ability to resolve pending legal matters; Vaxart’s ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks and uncertainties described in the “Risk Factors” sections of Vaxart’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the U.S. Securities and Exchange Commission, which are available on the SEC’s website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Hfx3TP7mrU0aIiBlsFXPtZ2wKam-_Ewot9QDFGH_tvEZzlXMZAANeJjx6jEHWHMwmT9-8mlN20KNRUl_V6k_E_UeuWayS3eWD0bRJcNysGf_10UdP3-GLOzoFZpUMN83caKEGJA_KuCd5rQx5AChO8aIEJkbj9vqI6mDVemIT5OYrkn0m7C1ePYjLDH7sEg8onqJMiY0wzzt_zJ0TBjV6R6Nqm5AlTQFphw4YtZe658=" rel="nofollow" target="_blank" data-mce-href="https://www.globenewswire.com/Tracker?data=Hfx3TP7mrU0aIiBlsFXPtZ2wKam-_Ewot9QDFGH_tvEZzlXMZAANeJjx6jEHWHMwmT9-8mlN20KNRUl_V6k_E_UeuWayS3eWD0bRJcNysGf_10UdP3-GLOzoFZpUMN83caKEGJA_KuCd5rQx5AChO8aIEJkbj9vqI6mDVemIT5OYrkn0m7C1ePYjLDH7sEg8onqJMiY0wzzt_zJ0TBjV6R6Nqm5AlTQFphw4YtZe658=" title="www.sec.gov">www.sec.gov</a>. The forward-looking statements in this press release speak only as of the date of this press release. Vaxart undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by applicable law.Contact Vaxart Media and Investor Relations FINN Partners IR@vaxart.com <img alt="" src="https://ml.globenewswire.com/media/YzMzYjNhNWItMDZhNi00M2IxLWJhOWYtMWYyMTg3YTZkMmIzLTEwMzA2ODItMjAyNi0wOC0yNi1lbg==/tiny/Vaxart-Inc-.png" />

GlobeNewswire Inc.

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn